A rrhythmogenic right ventricular (RV) cardiomyopathy (ARVC) is an inherited cardiomyopathy that is characterized by ventricular arrhythmias and an increased risk of sudden cardiac death (SCD). [1] [2] [3] [4] [5] This condition has been referred to with a variety of names, including arrhythmogenic RV dysplasia, ARVC, and arrhythmogenic cardiomyopathy. All of these terms refer to the same condition. For this review article, we use the term ARVC. Although structural abnormalities of the RV predominate, it is well recognized that left ventricular (LV) involvement is common, particularly in advanced disease, and that left-dominant forms occur. 2, 6 The pathological characteristic of ARVC/D is myocyte loss with fibrofatty replacement. Since the first detailed clinical description of the disorder in 1982, 1 significant advances have been made in understanding this disease. In the majority of patients, ARVC is a disease of desmosomal dysfunction. A pathogenic mutation can be identified in >60% of affected individuals. 6 Consistent with this, genetic testing has emerged as an important diagnostic tool and is important for cascade family screening. Once the diagnosis of ARVC is established, the single most important clinical decision is whether a particular patient's SCD risk is sufficient to justify placement of an implantable cardioverter-defibrillator (ICD). 2, 7 The importance of this decision reflects the fact that ARVC is a common cause of sudden death in young people 8, 9 and that SCD may be the first manifestation of the disease. [10] [11] [12] This decision is particularly important because these are often young patients who are expected to live for many years. Although an ICD can save lives in individuals with this disease, it is also well recognized that ICD therapy is associated with both short-and long-term complications. 13 The primary purpose of this article is to provide a review of risk stratification in patients with ARVC. This is important because decisions about the placement of an ICD are based on an estimate of a patient's risk of SCD, as well as their preferences and values. To place the issue of risk stratification in context, a brief review of ARVC is provided.
ARRHYTHMOGENIC RV CARDIOMYOPATHY
ARVC has an estimated prevalence of 1 per 5000 in the population. Patients usually present during the second to fifth decade of life with palpitations, lightheadedness, syncope, or, uncommonly, sudden dea th. 1, 2, [10] [11] [12] 14, 15 It is rare for patients with ARVC to have clinical signs or symptoms of ARVC before 12 years of age. It is also uncommon to first develop signs or symptoms of ARVC after the age of 60 years. 10, 14, 16 Symptoms are caused largely by the presence of ventricular arrhythmias. Heart failure (HF) is an uncommon and late manifestation of the disease. Figure 1 summarizes the presenting clinical features, clinical course, arrhythmias, and survival outcomes of 439 index patients diagnosed with ARVC. 14 The mean age at presentation was 36±14 years. Forty-eight index patients (11%) presented with cardiac arrest. Of these, 25 were resuscitated and 23 died and the diagnosis was established at autopsy. The median age at cardiac arrest was 25 years. An additional 220 index patients (50%) presented with a sustained ventricular arrhythmia (VA). An ICD was implanted in 212 of the 245 index patients (87%) with a sustained VA or resuscitated SCD compared with 139 of the 171 index patients (81%) presenting without a sustained VA. A sustained VA was seen during followup in more than two-thirds of the entire group of patients (n=301, 72%). Of the 65 index patients without an ICD, 31 (48%) experienced a sustained VA during follow-up. Among the index patients with an ICD, 10 died (3%): 2 of SCD, 3 of HF, 2 of a combination of HF and arrhythmias, and 3 of noncardiac causes. Among index patients without an ICD, 11 (17%) died during a median follow-up of 5 years, 10 as a result of a cardiac arrest and 1 of HF. The incidence of SCD was 16% in index patients without an ICD compared with 0.6% among those with an ICD (P<0.001). During long-term follow-up, 54 index patients (13%) developed symptomatic HF, and 18 (4%) had cardiac transplantation. Overall, 391 of the 416 index patients (94%) who presented alive were living at the last follow-up. Figure 2A and 2B shows the results of the Kaplan-Meier survival analysis by age for these 416 index patients for the following outcomes: any arrhythmogenic RV dysplasia/ cardiomyopathy-related symptoms, sustained VA, cardiac mortality, and cardiac transplantation.
ARVC is most commonly caused by mutations in desmosomal genes and is inherited in an autosomal dominant pattern with variable penetrance and expressivity. A recent study reported the genetic findings of a large transatlantic cohort of 577 patients from 241 unrelated families. 6 The majority of participants (n=463, 80%) were found to have a single PKP2 mutation with significantly fewer heterozygous carriers of mutations in other arrhythmogenic RV dysplasia/cardiomyopathyassociated genes. Among carriers of single mutations, premature truncating, splice-site, and missense mutations were identified in 342 (60%), 130 (23%), and 83 (14%) patients, respectively. Patients with SCD or ventricular fibrillation (VF) at presentation (n=36) were younger (median age, 23 versus 36 years; P<0.001) than those presenting with sustained monomorphic ventricular tachycardia (VT). Patients with multiple mutations (n=22, 4%) had significantly earlier occurrence of sustained VT/VF (mean age, 28±12 years), lower VT/ VF-free survival (P=0.037), and more frequent LV dysfunction (29%), HF (19%), and cardiac transplantation (9%) compared with those with only 1 mutation. DSP mutation carriers had a >4-fold increased occurrence of LV dysfunction (40%) and HF (13%) compared with PKP2 carriers. Missense mutation carriers had similar death/transplantation-free survival and VT/VF penetrance (P=0.137) compared with those with truncating or splice-site mutations.
MANAGEMENT OF ARVC
Management of patients with ARVC can be considered to be a 5-legged stool. The first leg is to be certain of the correct diagnosis. Misdiagnosis of ARVC is common because of misinterpretation of magnetic resonance imaging and possible lack of awareness of the 2010 Task Force Criteria. 17, 18 The diagnosis of ARVC is based on a scoring system with major and minor criteria using a combination of defects in RV morphology and function, characteristic depolarization/repolarization electrocardiographic abnormalities, correct identification of tissue pathology, VA, family history, and the results of genetic testing. The 2010 Task Force Criteria should be used to determine the presence or absence of ARVC. 17 One approach to this diagnostic classification is to use a point classification. Patients are diagnosed as having ARVC if they have 4 points, with major criteria equal to 2 points and minor criteria equal to 1 point. Patients who have a score of 3 points are classified as having probable ARVC, whereas those with 1 or 2 points are classified as not meeting criteria for ARVC. When considering these guideline recommendations, it is important to recognize that there is no single gold-standard diagnostic test. The second leg involves the prediction of the risk of a sustained VA to guide decisions about ICD implantation. This is the main focus of this review article and is discussed extensively later in this article. The third leg is to minimize ICD therapies. This involves a combination of pharmacological therapy with β-blockers, antiarrhythmic medications, and exercise restriction. These therapies need to be tested in randomized clinical trials. Catheter ablation is another important option for treatment of patients with ARVC who have VT. This therapy has been markedly improved by the use of epicardial ablation or a combination of endocardial and epicardial ablation for VT. [19] [20] [21] At present, this therapy can improve quality of life by decreasing the frequency of VT episodes. However, it has not been proved to be curative, has not been shown to reduce sudden death risk, and has not been shown to increase survival. It is for this reason that catheter ablation of VT is considered a palliative therapy in patients with ARVC, not a technique that can be used to reduce sudden death risk and the need for an ICD. Exercise restriction has been shown to be important to decrease the progression of the disease to reduce the likelihood of sustained VAs. [22] [23] [24] [25] [26] [27] The fourth leg is to prevent progression of the disease. A recent study compared paired echocardiograms obtained an average of 6.4 years apart in 85 patients with ARVC. 28 During this time, the RV size increased, and RV and LV function decreased. This publication, coupled with decades of experience, indicates that ARVC is a progressive condition. Although clinical studies have not been performed to identify therapies that slow the progression of disease, exercise restriction is likely very important in this regard. [22] [23] [24] [25] [26] [27] James et al 23 have reported that phenotypic expression of ARVC, sustained VAs, and the development of HF are related to exercise history. In this study, HF developed during follow-up only in endurance athletes (18% versus 0%). Similar findings have been reported by Saberniak et al. 26 It was notable that the study by Saberniak et al reported that 5 patients with ARVC, all athletes, underwent cardiac transplantation, whereas no nonathletes received transplantation. The fifth leg is cascade screening of family members. The widespread availability of genetic testing has greatly facilitated this process. Patients diagnosed with ARVC should undergo genetic testing. If a pathogenic mutation is identified, selected testing for this pathogenic mutation can be performed in first-degree family members to identify those at risk for the development of ARVC. If the same pathogenic mutation is identified in a family member, cardiac evaluation including an ECG, Holter, and echocardiography or magnetic resonance imaging should be performed, particularly after puberty. Exercise restriction in mutation carriers is also recommended. Repeat cardiac evaluation should be performed every 2 to 3 years. If no pathogenic mutation is identified in the proband, we generally recommend that cardiac testing, as described above, be performed in all first-degree family members every 2 to 3 years, depending on the level of physical activity.
RISK STRATIFICATION IN PATIENTS WITH ARVC
Since the first description of ARVC by Marcus et al 1 in 1982, considerable information has been published about risk stratification in patients with ARVC. This information has largely been the result of single-center reports and several small multicenter registries. The ultimate approach to risk stratification of patients by ARVC can best be determined with a prospective randomized study of ICD implantation. Unfortunately, this type of study has never been performed and in our opinion is unlikely to ever be carried out. Limitations in designing a randomized study include the fact that ARVC is a rare disease with a heterogeneous pattern of clinical presentation. In addition, there are insufficient data to select patients who are at risk for VT but not SCD in order to make a prospective randomized clinical trial acceptable from an ethics perspective.
In general, the risk that a patient with ARVC will experience a sustained VA or SCD reflects (1) whether the patient has previously experienced a sustained VA; (2) the extent of structural heart disease; (3) the degree of electrical instability, including the number of premature ventricular contractions (PVCs) in 24 hours or nonsustained VT; (4) cardiac syncope; (5) younger age; (6) male sex; (7) mutation status; and (8) vigorous or sustained exercise. We review the literature that pertains to each of these risk factors.
Over the past 25 years, a number of studies have been performed that have assessed the natural history of ARVC. 10, 14, [29] [30] [31] [32] [33] These studies have focused on the outcomes of populations of patients with ARVC without regard as to whether a decision had been made to implant an ICD (Table 1 ) and on defining the outcomes of patients who had an ICD implanted [34] [35] [36] [37] [38] [39] [40] [41] [42] (Table 2 ). Interpretation of results of these studies is challenging for many reasons. First, ARVC is an uncommon heterogeneous disease. The number of patients reported in these series is small. Second, the diagnostic criteria for ARVC have evolved over time. Diagnostic criteria for ARVC were initially published in 1994 43 and were revised in 2010. 17 Advanced magnetic resonance imaging and genetic testing have only recently become widely available. Third, no uniform standards for phenotyping patients with ARVC and for reporting outcomes have been developed. This makes comparison of published studies difficult. Furthermore, in all studies to date, phenotyping data are incomplete, which precludes multivariate analysis. Finally, adjunctive therapies in addition to ICD therapy have been different over time. These therapies include antiarrhythmic drugs, VT ablation, and exercise restriction. Virtually all studies that have described the natural history, incidence, and predictors of ICD therapy in patients with ARVC have failed to take exercise levels into consideration, reflecting the fact that the link between exercise and the complications of ARVC has only recently been appreciated. [22] [23] [24] [25] [26] [27] Table 1 lists the studies that have reported the outcomes of patients with ARVC regardless of ICD implantation.
14,29- 33 We described in detail the findings of the largest of these studies previously.
14 It can be appreciated that patients with ARVC are at significant risk of sudden death, cardiac death, and need for cardiac transplantation over time. Table 2 lists studies that have reported the outcomes of patients with ARVC who have undergone ICD implantation. These studies reveal that patients with ARVC in whom a decision has been made to implant an ICD are at high risk for having VA. During ≈32 to 106 months of follow-up, most studies report the incidence of an appropriate therapy for a sustained VA (VT or VF) to be between 40% and 70% and an incidence of an appropriate ICD therapy for ventricular fibrillation ventricular flutter (VF/VFL) to be ≈20%. Variables that have been associated with increased risk include a previous sustained VA, nonsustained VT, frequent PVCs, cardiac syncope, proband status, male sex, and the extent of structural heart disease.
Among these 8 studies, the most recent and largest study reporting the outcomes of ICD therapy in patients with ARVC was published in 2017. 41 This study reported the outcomes of 312 patients with ARVC (163 men; age at presentation, 33.6±13.9 years) who received an ICD. During a mean follow-up of 8.8±7.3 years, 186 subjects (60%) had an appropriate ICD therapy, and 58 (19%) had ICD therapy for VF/VFL (Figure 3 remained independent predictors of VF/VFL on multivariable analysis. Ninety-eight lead-or device-related complications occurred in 66 subjects (21%). Sixty-six of the 98 complications (67%) were lead related, and the remainder (32, 33%) were generator related. Six patients (6%) experienced decreased sensing on the RV lead requiring revision or replacement. Sixty-four of the 312 patients in this series (21%) had inappropriate ICD interventions. The overall mortality was 2%. Cardiac transplantation was required during follow-up in 4% of subjects. Relatively little is known about the outcomes of patients with ARVC who have a subcutaneous ICD implanted. 41, 44 Among the 312 patients with ARVC described in the recent large report of the outcomes of ICD therapy in patients with ARVC, 7 had a subcutaneous ICD implanted. 41 The clinical features and outcomes of these patients were not reported separately. Similarly, 15 of the 1637 patients (0.9%) who were included in the recently published postapproval study of the subcutaneous ICD had ARVC. The outcomes of this small subset of patients have not been reported separately. 44 The objective of the recent study by Brun and colleagues 31 was to examine risk stratification in patients with ARVC who did not have an ICD. This is important because it is well recognized that using appropriate ICD therapies for VF and VFL overestimates the mortality benefit of ICD therapy. In this study, 88 probands from 3 centers were followed up for an average of 9.1±7.7 years. There were 12 deaths (14%). Among the 36 patients who had never had a sustained VA before enrollment, there were no deaths. There were 5 deaths caused by VA in the 52 patients who had sustained VA before registry enrollment. A relationship was observed between index VT and allcause mortality (P=0.052). Among the 5 patients who had an arrhythmic death, the LV ejection fraction at baseline was significantly lower (P=0.04) that that of those who did not have an arrhythmic death. No relationship was observed between mortality and syncope, male sex, age, results of EPS, T-wave inversion, QRS duration, and use of β-blockers. The authors concluded that risk factors for arrhythmic events include previous sustained or nonsustained VT and decreased LV function. These results are in agreement with those of previous outcome studies on patients with ARVC with an ICD.
SELECTED TOPICS IN RISK STRATIFICATION OF PATIENTS WITH ARVC Sustained VAs as a Risk Marker
Patients with ARVC who have experienced a sustained VA (sustained VT, VFL, or VF) are at considerable risk of developing recurrent sustained VT and VF (or VFL, defined as a cycle length ≤240 milliseconds). 33, 37, 41 This supports a recommendation for ICD implantation in these patients. Patients with ARVC who have hemodynamically stable VT may be at sufficiently low risk to justify that an ICD not be implanted. For example, in 2003, Corrado et al 34 reported that this subset of patients had only a 1% subsequent risk of VF. Whether this finding is reproducible is not known because few other studies have subdivided patients with sustained VT into those with hemodynamically stable and those with hemodynamically unstable VT. Some insight into this topic is provided by the recent study by Mazzanti et al. 33 In this large series, hemodynamically stable VT was a predictor of the development of a lethal VA. These findings are consistent with the Johns Hopkins clinical experience, which supports the concept that patients with ARVC who experience a sustained VA, regardless of hemodynamic stability, have a sufficiently high risk of sudden death to warrant placement of an ICD. 
Proband Versus Family Member
Probands have a higher arrhythmic risk than family members with ARVC. One of the largest studies to evaluate this was by Bhonsale et al 39 ( Figure 5 ). The reason may be that family members are generally diagnosed earlier in the course of the disease. The diagnosis of ARVC in a first-degree family member is a major criterion for ARVC. 17 As a result, evidence of ARVC such as T-wave inversion in leads V 1 and V 2 after the age of 12 years and >1000 PVCs per 24 hours will confirm the diagnosis of ARVC in a family member. To the degree that the extent of disease predicts arrhythmic risk in ARVC, it is understandable that proband status is an important variable for risk stratification.
Cardiac Syncope Is Important for Risk Stratification in ARVC
A recent history of cardiac syncope is an important risk marker in patients with ARVC. This link was recognized by Marcus et al 3 and reinforced by studies that described the clinical characteristics of ARVC in patients who died suddenly. [10] [11] [12] It was striking that there was a subset of patients with unexplained syncope occurring within a year or within months of SCD. This link has also been confirmed in reports of ICD therapy in patients with ARVC. In a study by Corrado et al, 38 of 106 patients with ARVC, syncope, and a previous episode of sustained VT or VF were important predictors of ICD therapy and VT/VF. These findings have recently been confirmed in a large report examining predictors of ICD therapy in 312 patients with ARVC. 41 Syncope was identified as one of the predictors of ICD therapy for VF/VFL (HR, 1.85; 95% CI, 1.10-3.11; P=0.021). 41 Because in young individuals syncope most commonly has vasovagal causes, careful attention should be paid to defining the circumstances and details of a syncopal episode and considering this a risk factor for sudden death only in cases of a probable arrhythmic nature.
Evidence of Electric Instability as a Risk Marker
It is now well recognized that electric instability is an important risk factor for the development of a sustained VA in patients with ARVC. Multiple studies have reported that the presence of nonsustained VT and frequent PVCs on 24-hour Holter are risk factors for a sustained VA. 37, 38, 41 In a series of 84 patients with ARVC who underwent implantation of an ICD for primary prevention, both frequent PVCs and nonsustained VT were identified as significant predictors of appropriate ICD therapy. 38 Furthermore, these authors reported that the greater the number of PVCs over a 24-hour period, the higher the arrhythmic risk. Another marker of electric instability is inducibility of sustained VT during an EPS. Several series 36, 37, 39, 41, 45 have identified inducibility at electrophysiology testing as a risk marker in patients with ARVC who have undergone implantation of an ICD. Although others have not found that electrophysiology testing is predictive, 38 our experience supports the role of electrophysiology testing for risk stratification, especially when a patient has an EPS for diagnostic evaluation. One of the most important differential diagnoses to consider when evaluating a patient with ARVC and VT is idiopathic outflow tract VT. Electrophysiology testing not only can be helpful in distinguishing these 2 conditions but also can lead to the cure of idiopathic RVOT VT in appropriate patients by mapping and catheter ablation. 
Severity of RV and LV Disease
Another important variable for risk stratification is the extent of RV and LV disease. Studies have shown that arrhythmic risk is greater in those with more severe disease even if different variables are used to assess the extent of disease. For example, studies have shown that patients with a greater number of T-wave inversions on a 12-lead ECG have a higher arrhythmic risk. 39, 40 There are reports that patients with more extensive abnormalities detected on a signal-averaged ECG have a higher arrhythmic risk. 46 Several studies have shown that patients with more extensive RV or LV disease have a higher arrhythmic risk. 35, 42, 47 Other studies have reported that patients with a larger area of scar, as assessed by electroanatomic mapping, have more arrhythmias than those with a smaller scar. 48 This literature supports the view that those patients with more extensive myocardial disease, as assessed by a number of metrics, are at higher arrhythmic risk than those with little to no structural disease.
Exercise
Another variable for risk stratification is whether the patient with ARVC should participate in sustained or high-level exercise. [22] [23] [24] [25] [26] [27] 49 Over the past 5 years, a number of studies have linked ARVC onset or progression with exercise. These studies have shown that endurance exercise can evoke an earlier presentation of ARVC and that exercising patients have more severe clinical manifestations of disease such as earlier onset of VAs, structural dysfunction, HF, and need for cardiac transplantation
The role of exercise in patients with ARVC and the important question of a safe exercise threshold have been reported by the Johns Hopkins ARVC Program. 24 These studies have shown that patients with ARVC should not engage in high-level or endurance exercise, regardless of their genotype. Although it might be potentially safe for asymptomatic mutation carriers to practice the level of exercise as suggested for a healthy adult as recommended by the American Heart Association, more research is needed to determine the threshold trigger of exercise that produces symptomatic ARVC.
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What About a Role for Sex and Genotype?
Men with ARVC are at higher arrhythmia risk than women.
14,41,49-52 Although the specific pathophysiological basis for this observation is unclear, it has been suggested that the reason may be more frequent and intense exercise by men. Others have proposed that this is more closely linked to cellular mechanisms.
Genotype is also of prognostic value. A number of studies have reported that carriers of multiple mutations in the same desmosomal gene or mutations in ≥2 genes are at higher arrhythmic risk than those with a single mutation. 6, 53 It is noteworthy that in a multivariable model analysis, multiple desmosomal gene mutations and male sex were independent predictors of lifetime major arrhythmic events with an HR of 3.7 and 2.7, respectively. 54 It is also recognized that certain ARVC-causing genetic defects may be considered risk factors for SCD. This is especially the case for the "nondesmosomal" TMEM43-p.S358L missense mutation, 55 which has been shown to be fully penetrant and highly lethal. However, this founder mutation is rare and is found almost exclusively in individuals in Newfoundland. The presence of phenotypic expression has been shown to be a prerequisite for malignant VAs and SCD. In a cohort of ARVC desmosomal gene mutation carriers who were prospectively investigated during a long-term follow-up (8.5 years), Zorzi et al 56 found that major arrhythmic events generally occurred in desmosomal gene mutation carriers who fulfilled International Task Force diagnostic criteria and had major risk factors. Desmosomal gene mutation carriers without a definite ARVC phenotypic expression had an uneventful clinical course, except for a 15-year-old desmoplakin gene mutation carrier with previous normal electrocardiographic and echocardiographic findings who died suddenly during sleep 2 years later. Postmortem evaluation demonstrated the presence of an epicardial scar in the inferolateral LV region. This finding suggests that lethal VAs during the concealed phase of ARVC may be the result of the low sensitivity of routine clinical tests such as ECG and echocardiography for the detection of early/minor arrhythmogenic phenotypic substrates such as an isolated epicardial scar of the LV, for which detection requires more sophisticated imaging technology such as contrast-enhanced cardiac magnetic resonance.
Further complicating this issue is that the 2010 Task Force Criteria have shown relatively poor performance for diagnosis (not to mention risk stratification) of isolated LV disease. 17 These data were recently confirmed by the study of te Riele et al, 57 who reported that electric abnormalities on electrocardiographic and Holter monitoring precede detectable structural abnormalities in ARVC mutation carriers. Among ARVC mutation carriers, the presence of both electric and structural abnormalities on cardiac magnetic resonance identified patients at high risk for arrhythmic events who may benefit from ICD implantation.
Implications for ICD Therapy
Recently, an International Task Force of experts from both Europe and the United States produced a consensus document on the treatment of ARVC. 7 This International Task Force document provided a summary of existing evidence and a set of recommendations for ICD implantation in patients with ARVC. The document defined 3 groups of patients with ARVC according to their arrhythmic risk ( Figure 6 ). The high-risk group includes patients with a history of cardiac arrest or sustained VT and those with severe RV or LV dysfunction. The indication for ICD implantation in this subset of patients was Class I. The intermediate-risk category included patients with ≥1 major risk factors (cardiac syncope, nonsustained VT, or moderate RV or LV dysfunction in whom implantation is reasonable; Class IIa). A third, lower-risk group was defined as those with ≥1 "minor" risk factors (eg, frequent PVCs, inducible VT at EPS, male sex, complex genotype, younger age, T-wave inversion on V 4 and beyond). For these patients, ICD implantation can be considered, especially if there are multiple risk factors, but should not be systematically performed. Finally, there is a low-risk group in whom the risk of SCD was not sufficiently high to recommend ICD implantation. This includes gene carriers who do not meet diagnostic criteria for ARVC and patients who meet the criteria but do not have high-risk markers for SCD. When considering whether to implant an ICD in a patient with ARVC, it is important to note that a family history of SCD, even in a first-degree relative, is not a risk marker for SCD. Because a family history of ARVC or a pathogenic mutation is a major diagnostic criterion for ARVC, these individuals can meet the diagnostic criteria for ARVC in the absence of significant structural or arrhythmic evidence of the disease. This group of individuals is at much lower risk of sudden death, especially if they refrain from vigorous or competitive exercise. Finally, patient preferences and values are important and should be respected. Information available concerning risk stratification for sudden death is derived primarily from single-center experiences and incomplete phenotyping.
Once a decision is made to implant an ICD, a final decision concerns which type of ICD to implant. In the absence of a clear indication for atrial pacing, single-chamber ICDs are preferred because the risk of early and late complications is reduced. Few data are currently available to guide the decision as whether to implant a subcutaneous ICD or a standard endocardial ICD. The benefits of avoiding an endocardial lead in young people must be balanced against the shorter battery life, the increased risk of inappropriate therapies, and the absence of antitachycardia pacing for VT termination. For patients undergoing ICD implantation for primary prevention, a strong argument can be made for a subcutaneous ICD, whereas for patients who present with sustained monomorphic VT, an endocardial device may have clear advantages because the risk of recurrent sustained VT is increased in this subset of patients. We hope that new studies will be available soon that will provide data to help guide this important decision.
Conclusions
Risk stratification is important for the management of patients with ARVC. The most important parameters to consider when determining arrhythmic risk include electric instability, including the frequency of PVCs and sustained VA; proband status; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or a mutation in TMEM43; and agreements to restrict exercise and to eliminate participation in competitive or endurance exercise. 
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